中国深圳市南山区前海大道前海嘉里商务中心 T2 栋 1401A 室 邮政编码 518054 电话: (86-755) 2155-7000 传真: (86-755) 2155-7099 北京市竞天公诚（深圳）律师事务所 关于福建福昕软件开发股份有限公司 调整 2022 年及 2024 年限制性股票激励计划授予价格 相关事项之法律意见书 致：福建福昕软件开发股份有限公司 北京市竞天公诚（深圳）律师事务所（以下简称"本所"）接受福建福昕软件 开发股份有限公司（以下简称"福昕软件"或"公司"）的委托，就公司调整 2022 年及 2024 年限制性股票激励计划授予价格事宜（以下简称"本次调整"）担任专 项法律顾问，并出具《北京市竞天公诚（深圳）律师事务所关于福建福昕软件开 发股份有限公司调整2022年及2024年限制性股票激励计划授予价格相关事项之 法律意见书》（以下简称"本法律意见书"）。 为出具本法律意见书，本所律师审阅了《福建福昕软件开发股份有限公司 2022 年限制性股票激励计划（草案）》（以下简称"《2022 年限制性股票激励计划 （草案）》"）、《福建福昕软件开发股份有限公司 2024 年限制性股票激励计划 ...

证券代码：688095 证券简称：福昕软件 公告编号：2025-031 福建福昕软件开发股份有限公司 关于使用闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 福建福昕软件开发股份有限公司（以下简称"公司"）于 2025 年 6 月 20 日 召开第四届董事会第二十四次会议和第四届监事会第二十三次会议，分别审议通 过了《关于使用闲置自有资金进行现金管理的议案》，同意公司使用不超过人民 币 10 亿元的闲置自有资金进行现金管理。在确保不影响公司主营业务正常开展， 保证运营资金需求和风险可控的前提下，使用闲置自有资金用于购买安全性高、 流动性好的投资产品（包括但不限于结构性存款、定期存款、通知存款、大额存 单、协定存款、证券公司保本型收益凭证、信托产品及国债逆回购等），且该等 现金管理产品不得用于质押，不得实施以证券投资为目的的投资行为。使用期限 自第四届董事会第二十四次会议审议通过之日起 12 个月内有效。在不超过前述 额度及期限范围内，资金可循环滚动使用。具体事项由公司财务部负责组织实施。 该事 ...

公司监事会认为：因 2024 年年度权益分派实施完毕，公司对 2022 年、2024 年限制性股票激励计划授予价格进行相应调整，符合《上市公司股权激励管理办 法》《2022 年限制性股票激励计划（草案）》及《2024 年限制性股票激励计划（草 案）》中关于授予价格调整方法的规定，不存在损害公司及股东利益的情形。因 此，监事会同意 2022 年限制性股票激励计划授予价格（含预留）调整为 32.83 元/股，2024 年限制性股票激励计划授予价格调整为 20.04 元/股。 证券代码：688095 证券简称：福昕软件 公告编号：2025-029 福建福昕软件开发股份有限公司 第四届监事会第二十三次会议决议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 监事会会议召开情况 福建福昕软件开发股份有限公司（以下简称"公司"）第四届监事会第二十 三次会议通知于 2025 年 6 月 17 日以电子邮件方式发出，于 2025 年 6 月 20 日在 福州市鼓楼区软件大道 89 号福州软件园 G 区 5 号楼公司会议室以现场结合 ...

证券代码：688095 证券简称：福昕软件 公告编号：2025-028 福建福昕软件开发股份有限公司 第四届董事会第二十四次会议决议公告 表决结果：赞成 5 票，反对 0 票，弃权 0 票，表决通过。 回避表决情况：董事 George Zhendong Gao、翟浦江作为关联董事，回避对 该议案的表决。 （二）审议通过《关于使用闲置自有资金进行现金管理的议案》 一、董事会会议召开情况 福建福昕软件开发股份有限公司（以下简称"公司"）第四届董事会第二十 四次会议通知于 2025 年 6 月 17 日以电子邮件方式发出，于 2025 年 6 月 20 日在 福州市鼓楼区软件大道 89 号福州软件园 G 区 5 号楼公司会议室以现场结合通讯 的方式召开。会议应到董事 7 名，实际出席董事 7 名，公司监事、高级管理人员 列席本次会议。本次会议由公司董事长熊雨前先生主持，会议的召开符合《中华 人民共和国公司法》《中华人民共和国证券法》等法律、法规、规范性文件及《公 司章程》的有关规定。 二、董事会会议审议情况 （一）审议通过《关于调整 2022 年、2024 年限制性股票激励计划授予价格 的议案》 因公司 2024 ...

Industry Rating - The industry rating is maintained at "Outperform" [1] Core Insights - The report suggests that the years 2025-2026 are expected to mark the commercialization of AI Agents, driven by advancements in large model capabilities and the introduction of key players like OpenAI, Anthropic, Microsoft, and Google [2][3] - The total addressable market (TAM) for AI Agents is estimated at approximately 3.61 trillion yuan, with significant opportunities in vertical industries such as IT and finance [2][3] - AI Agents are projected to replace specific standardized roles in various sectors, with a focus on enhancing productivity and ROI for businesses [3][48] Summary by Sections Investment Rating - The report maintains a rating of "Outperform" for the industry [1] Market Potential - The total addressable market (TAM) for AI Agents is estimated at 3.61 trillion yuan, calculated based on total salary levels, replacement rates, and efficiency optimization [50][54] - The report highlights six core scenarios where AI Agents are expected to penetrate first, including coding, banking, human resources, legal, cybersecurity, and customer service [61][62] Key Industry Insights - AI Agents are anticipated to significantly impact the banking sector, with 54% of jobs having a high potential for automation, leading to an estimated TAM of 1774.32 billion yuan in this field [71][77] - In the coding sector, AI is expected to automate up to 99% of coding tasks by the end of 2025, with a TAM of approximately 4357.84 billion yuan [63][68] - The report emphasizes that AI Agents will first replace roles in high-salary, white-collar industries such as finance, IT, and law, where the ROI for AI implementation is more favorable [55][57] Company Recommendations - The report suggests monitoring companies involved in general office applications and enterprise SaaS, as well as those in vertical markets like banking, human resources, and cybersecurity [3][4]

Group 1: Global AI Outlook - The report highlights a new paradigm in AI development characterized by new scaling, new architecture, and new total addressable market (TAM) opportunities [1] - The demand for computing power is expected to rise due to advancements in both training and inference processes, potentially unlocking new TAMs [1][3] - The report maintains a positive outlook on AI industry investments, anticipating that global AI applications will enter a performance harvesting phase [1] Group 2: Model Development - The pre-training scaling law is anticipated to open a new starting point for model development, with significant innovations in architecture being explored [2][23] - The report notes that the classic transformer architecture has reached a parameter scale bottleneck, with existing public data nearly exhausted [2][20] - Major tech companies are experimenting with new architectures, such as Tencent's Hunyuan TurboS and Google's Gemini Diffusion, which may accelerate scaling law advancements [23][24] Group 3: Computing Power Demand - The report identifies a clear long-term upward trend in computing power demand, driven by both training and inference needs [3][32] - New scaling paths are emerging in the post-training phase, with ongoing exploration of new architectures that may reignite pre-training demand narratives [3][33] - The deployment of large-scale computing clusters, such as OpenAI's StarGate, is expected to support the exploration of pre-training [38] Group 4: Application Development - The report indicates that the rapid advancement of agent applications is leading to a performance harvesting phase for global AI applications [4][67] - The commercialization of agent products is accelerating, with domestic AI applications quickly iterating and entering the market [4][67] - The report emphasizes that agent applications are evolving from simple tools to complex solutions, with significant growth expected in various sectors [5][68] Group 5: Business Model Transformation - The shift from traditional software delivery to outcome-based delivery is highlighted as a key trend, with quantifiable ROI accelerating the adoption of agent applications [5] - Specific sectors such as consumer-facing scenarios (advertising, e-commerce) and AI in marketing/sales are expected to lead in commercialization due to their inherent advantages [5][67] - The report notes that AI applications in HR are transitioning from efficiency tools to strategic hubs, indicating a broader transformation in business models [5][67]

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

Core Viewpoint - The announcement of share reduction plans by directors and senior management of Foxit Software indicates potential changes in shareholder structure and may impact market perception of the company [1][2]. Shareholding and Reduction Plans - Director and Vice President Zhai Pujiang holds 857,937 shares, representing 0.9383% of the total share capital of 91,439,524 shares [1]. - Secretary of the Board and Financial Officer Li Weilan holds 23,551 shares, representing 0.0258% of the total share capital [1]. - Zhai Pujiang plans to reduce his holdings by up to 50,000 shares (0.0547% of total shares) within three months after a 15-trading-day period from the announcement [2]. - Li Weilan plans to reduce his holdings by up to 5,800 shares (0.0063% of total shares) within the same timeframe [2]. Financial Performance - For the year 2024, Foxit Software reported revenue of 711.14 million yuan, a year-on-year increase of 16.44% [2][3]. - The net profit attributable to shareholders was 26.96 million yuan, while the net profit after deducting non-recurring gains and losses was -202 million yuan [2][3]. - The net cash flow from operating activities was -64.34 million yuan, indicating a decline compared to the previous year [2][3]. Historical Financial Data - In 2023, the company achieved revenue of 611 million yuan, a growth of 5.33%, but reported a net loss of 90.94 million yuan [3][4]. - In 2022, revenue was 580 million yuan, with a net loss of 1.74 million yuan [4]. - In 2021, revenue was 541 million yuan, with a net profit of 46.24 million yuan, but a significant decrease in net profit compared to the previous year [4]. Initial Public Offering (IPO) and Fundraising - Foxit Software raised a total of 2.872 billion yuan in its IPO, with a net amount of 2.586 billion yuan after deducting expenses [5]. - The company initially planned to raise 407 million yuan for various projects, but the final amount exceeded the original plan by 2.179 billion yuan [5]. - The IPO was conducted on September 8, 2020, with an issuance price of 238.53 yuan per share [4][5].

Group 1 - The core point of the announcement is that two executives of Foxit Software, Zhai Pujiang and Li Weilan, plan to reduce their shareholdings in the company due to personal financial needs [1][2] - Zhai Pujiang holds 857,937 shares, representing 0.9383% of the total share capital, and plans to sell up to 50,000 shares, which is 0.0547% of the total share capital, between June 30, 2025, and September 29, 2025 [1] - Li Weilan holds 23,551 shares, accounting for 0.0258% of the total share capital, and intends to sell up to 5,800 shares, which is 0.0063% of the total share capital, within the same timeframe [1] Group 2 - The planned share reduction is consistent with previous commitments made by the executives regarding their shareholding [2] - The reduction plan complies with relevant laws and regulations and is not expected to significantly impact the company's governance structure or ongoing operations [2] - There is uncertainty regarding the implementation of the reduction plan, and investors are advised to be aware of investment risks [2]

证券代码：688095 证券简称：福昕软件 公告编号：2025-027 福建福昕软件开发股份有限公司 董事、高级管理人员减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 董监高持股的基本情况 截至本公告披露日，本次拟减持福建福昕软件开发股份有限公司（以下简称 "公司"）股份的减持主体持股情况如下： 1、公司董事、副总裁翟浦江先生持有公司股份 857,937 股，占公司总股本 91,439,524 股的比例为 0.9383%；其股份来源于公司首次公开发行股票并上市前 持有的股份、公司实施资本公积金转增股本取得的股份以及股权激励获授归属取 得的股份，均为无限售流通股。 2、公司董事会秘书、财务负责人李蔚岚女士持有公司股份 23,551 股，占公 司总股本 91,439,524 股的比例为 0.0258%；其股份来源于二级市场增持的股份、 公司实施资本公积金转增股本取得的股份以及股权激励获授归属取得的股份，均 为无限售流通股。 减持计划的主要内容 翟浦江先生基于自身资金需求，计划自本公告 ...